Holen Sie sich die Stockscreener-App
12.32
6.70%
-0.885
Handel nachbörslich:
12.40
0.08
+0.65%
Schlusskurs vom Vortag:
$13.21
Offen:
$13.33
24-Stunden-Volumen:
74,652
Relative Volume:
0.88
Marktkapitalisierung:
$20.36M
Einnahmen:
$368.00K
Nettoeinkommen (Verlust:
$-9.54M
KGV:
-25.73
EPS:
-0.4788
Netto-Cashflow:
$-9.47M
1W Leistung:
+5.48%
1M Leistung:
+159.37%
6M Leistung:
+1,725%
1J Leistung:
+1,289%
1-Tages-Spanne:
$12.25
$13.93
1-Wochen-Bereich:
$10.30
$13.93
52-Wochen-Spanne:
$0.35
$13.93
Lexaria Bioscience Corp Stock (LEXX) Company Profile
Firmenname
Lexaria Bioscience Corp
Sektor
Branche
Telefon
250-765-6424
Adresse
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
12.32 | 18.62M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
557.96 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
843.47 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,053.46 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
148.87 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.87 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten
Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - Kalkine
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Nigeria
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Lexaria Bioscience regains Nasdaq bid-price compliance, listing continued - TradingView
Delisting risk eases as Lexaria (NASDAQ: LEXX) regains bid-price compliance - Stock Titan
Lexaria Bioscience enters MTA with PegBio - TipRanks
LEXX Looks 64.3% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Signs PegBio Deal to Test DehydraTECH With GLP-1 Diabetes Drug - TipRanks
Lexaria Bioscience Corp. Enters Material Transfer Agreement with Pegbio Co., Ltd - marketscreener.com
Lexaria enters partnership with PegBio for GLP-1 drug delivery By Investing.com - Investing.com Australia
Lexaria enters partnership with PegBio for GLP-1 drug delivery - Investing.com
Lexaria Enters a Material Transfer Agreement With PegBio - Investing News Network
Lexaria Enters a Material Transfer Agreement with PegBio - TradingView
Lexaria and PegBio Plan Animal Studies on a GLP-1 Molecule - Stock Titan
Lexaria Bioscience Received Notice of Delisting - TradingView
Lexaria Bioscience Corp (LEXX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Stock Price Forecast. Should You Buy LEXX? - StockInvest.us
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) Stock News Today - TradingKey
Lexaria Bioscience Corp Authorizes 1-For-15 Reverse Stock SplitSEC Filing - TradingView
Lexaria Bioscience plans 1-for-15 reverse stock split By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp (LEXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexaria Bioscience Corp. Revenue Breakdown – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LEXX|Lexaria Bioscience Corp|Price:0.559|Chg%:-0.011 - TradingKey
Enterprise value to revenue forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Cash Flow - TradingKey
Lexaria Bioscience Corp (LEXX) Income Statement - TradingKey
LEXX|Lexaria Bioscience Corp|Price:11.495|Chg%:+1.175 - TradingKey
LEXX|Lexaria Bioscience Corp|Price:11.270|Chg%:-0.240 - TradingKey
Lexaria Bioscience Corp (LEXX) Earnings Date & Reports & Earnings News - TradingKey
Lexaria Bioscience Corp (LEXX) Institutional Confidence - TradingKey
Price to book forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp. 10-Q Q3 2026: Financial Results, NASDAQ Listing, and Key Highlights - Minichart
Lexaria Bioscience narrows Q3 loss to $(0.08) per share - scanx.trade
LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings - Quiver Quantitative
Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary - TradingView
Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid - Stock Titan
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026 - marketscreener.com
Lexaria Bioscience Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Lexaria reports pharmaceutical partnership discussions at BIO - Investing.com
Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com - Investing.com Nigeria
Lexaria Updates Business Development - Investing News Network
Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows - Stock Titan
LEXXLexaria Bioscience Corp Forecast, Target Price - Finviz
Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX) - TradingView
Lexaria Begins Dosing in Human Study Evaluating Oral Semaglutide Formulations Against Wegovy - citybuzz -
Finanzdaten der Lexaria Bioscience Corp-Aktie (LEXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):